#DDDD $LBPS is primed to address the Covid treatment need & 4D has a broad pipeline of live bio therapeutics.

Significantly de-risked with MicroRx discovery platform approach.

5 key readouts due by Feb 2021! + FDA accelerated approval.

Remember Covid trial results in Q4 2020!

#DDDD $LBPS MRx-4DP0004: UNIQUE IMMUNOMODULATORY PROFILE SUITABLE FOR COVID-19

MRx-4DP0004 has a complementary mechanism to standard-of-care glucocorticoid dexamethasone; demonstrated safety with glucocorticoids in clinic.

#DDDD $LBPS

MRx-4DP0004 Could prevent hospitalised patients from progressing and requiring ventilation or critical care.

Application during stage II, pulmonary stage

#DDDD $LBPS MRx-4DP0004 DRAMATICALLY REDUCES NEUTROPHILS.

High neutrophils increasingly understood to be a key driver of COVID symptom pathology & indicator of disease severity.

4DP0004 Demonstrated efficacy in both prophylactic (defending or protecting) & therapeutic settings

#DDDD $LBPS SYSTEMIC IMMUNOMODULATORY ACTIVITY OF MRx-4DP0004 IS NOT LIMITED TO LUNGS

More severe cases of COVID-19 are associated with systemic hyperinflammation

#DDDD $LBPS MRx-4DP0004 REDUCES CYTOKINES AND CHEMOKINES

High mortality rate of COVID-19 may be due to hyper-inflammatory response and cytokine storm syndrome caused by uncontrolled activation of the immune system.

#DDDD $LBPS MRx-4DP0004 INCREASES REGULATORY T CELLS

Patients with COVID-19 have lower levels of regulatory T cells, and to a greater extent in severe cases.

#DDDD $LBPS MRx-4DP0004 REGULATES EXCESSIVE INNATE ACTIVATION WITHOUT SUPPRESSING ADAPTIVE IMMUNE RESPONSE.

Maintenance of an appropriate anti-viral adaptive immune response is key to viral clearance and Covid-19 disease resolution.

#DDDD $LBPS MRx-4DP0004 INCREASES IMMUNE CELL TYPES REPORTED TO HAVE IMPORTANT ROLES IN COVID-19 PATIENTS’ SYMPTOMATIC RECOVERY

4DP0004 stimulates follicular helper T (Tfh) cells & activated CD19+ B cells – both reported to have important roles in patients symptomatic recovery

#DDDD $LBPS MRx-4DP0004 SIGNIFICANTLY REDUCES IMMUNE INFILTRATION AND PROTECTS LUNG HISTOLOGY

Covid-19. Reduced immune infiltration is associated with strong reduction in peribronchiolar and perivascular immune infiltration, and improved lung histopathology

#DDDD $LBPS ANTI-INFLAMMATORY ACTIVITY DEMONSTRATED IN MODEL OF SEVERE NEUTROPHILIC ASTHMA

- Reduced production in the lung of chemokines involved in neutrophil trafficking
- Significantly reduced airway neutrophil infiltration
- Demonstrated efficacy, prophylactic & therapeutic